Q1FY21 results: Ipca Laboratories net profit jumps 244 per cent YoY to Rs 445.68 crore

Ipca Laboratories Ltd., an international pharmaceutical company announced its quarterly results on August 10, 2020. The company posted a consolidated net profit of Rs 445.68 crore for Q1FY21, which increased by 244.34 per cent YoY, as compared to Q1FY20 when it reported Rs 129.43 crore.                                                                                                                                 

The consolidated net sales reported in Q1FY21 came in at Rs 1,534.4 crore, which increased by 42.31 per cent YoY from Rs 1,078.19 crore in Q1FY20. The revenue from formulations business jumped by 37% YoY to Rs 953.05 crore and revenue from active pharmaceutical ingredient (API) business jumped 72% YoY to Rs 513.29 crore. At EBITDA level, the company stood at Rs 588.32 crore in Q1FY21 that increased by 196.05 per cent YoY. For Q1FY20, it posted an EBITDA of Rs 198.72 crore.                                                                                                                                                       

EBITDA margin as of Q1FY21 was at 38.34 per cent that increased by 19.91 per cent YoY. The net profit margin in Q1FY21 came in at 29.05 per cent, which increased by 17.05 per cent YoY. The net profit margin in Q1FY20 was at 12 per cent.                                                                                     

Ipca Laboratories is a vertically integrated pharmaceutical company which produces finished dosage forms and active pharmaceutical ingredients. Reacting to the results, the share traded at its new 52 week high of Rs 2,175 on BSE. The share closed with gains of 7.36 per cent at Rs 2,099 on BSE.